| Identification | Back Directory | [Name]
5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[7-(difluoromethyl)-3,4-dihydro-6-(1-methyl-1H-pyrazol-4-yl)-1(2H)-quinolinyl]-1,4,6,7-tetrahydro-N-methyl-1-(4-piperidinyl)- | [CAS]
2484741-78-6 | [Synonyms]
CBP/p300 ligand 2
5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[7-(difluoromethyl)-3,4-dihydro-6-(1-methyl-1H-pyrazol-4-yl)-1(2H)-quinolinyl]-1,4,6,7-tetrahydro-N-methyl-1-(4-piperidinyl)- | [Molecular Formula]
C27H34F2N8O | [MOL File]
2484741-78-6.mol | [Molecular Weight]
524.61 |
| Chemical Properties | Back Directory | [Boiling point ]
800.7±65.0 °C(Predicted) | [density ]
1.46±0.1 g/cm3(Predicted) | [solubility ]
DMSO : 200 mg/mL (381.24 mM; Need ultrasonic) | [form ]
Solid | [pka]
14.19±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
CBP/p300 ligand 2 is a ligand for target protein for PROTAC of dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP[1].
CBP/p300 ligand 2 (example 229) has no toxicity to LNCaP prostate cancer cells[1]. | [References]
[1]. Jing Liu, et al. Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use. O2020173440A1. |
|
|